Skip to content

Individualized Target Modeling and Brain Network Plasticity Mechanism of rTMS for Post-Stroke Cognitive Impairment Guided by fNIRS

Individualized Target Modeling and Brain Network Plasticity Mechanism of rTMS for Post-Stroke Cognitive Impairment Guided by fNIRS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127671
Enrollment
Unknown
Registered
2026-07-05
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Individualized Precision Group:Based on fNIRS and machine learning, an individualized target model for PSCI was constructed to output individualized target coordinates for each patient. Precise naviga
Traditional empirical group:Stimulation site: left dorsolateral prefrontal cortex (DLPFC). rTMS was applied at 10 Hz, 100% RMT, with 2000 pulses per session, for 4 consecutive weeks.
Sham stimulation group:Based on fNIRS and machine learning, an individualized target model for PSCI was constructed to output individualized target coordinates for each patient. Precise navigation and

Sponsors

Hubei Provincial Government Directly-Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for cerebral infarction, confirmed by head CT or MRI examination; 2. Aged 30–85 years; 3. First onset, disease course 1–6 months; 4. No cognitive impairment before onset, with MoCA score 11–26 after stroke; 5. No severe aphasia, able to cooperate with various functional assessments, stable vital signs, and no progressive neurological symptoms; 6. The patient or their family members are fully informed and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with skull defects who are ineligible for the relevant treatment; 2. Patients with a history of psychiatric disorders or other major neurodegenerative dementia diseases; 3. Patients with severe cardiac, hepatic, renal or other organ damage, severe aphasia, visual or auditory impairment, who are unable to cooperate with treatment and relevant assessments; 4. Patients with cognitive impairment caused by other factors such as drugs or intoxication; 5. Patients with a history of epilepsy or contraindications to rTMS; 6. Patients currently participating in other clinical trials that may affect the outcomes of this study.

Design outcomes

Primary

MeasureTime frame
Cognitive Function;Quantifying/measuring executive function;Hemodynamic measures during resting state and a 1?back working memory task;

Secondary

MeasureTime frame
Adverse events;

Countries

China

Contacts

Public ContactXia Wenguang

Hubei Provincial Government Directly-Affiliated Hospital

docxwg@163.com+86 27 8723 3488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026